HEIDELBERG, Germany, September 13, 2018 /PRNewswire/ -- ViraTherapeutics sale marks third exit from EMBL Ventures' current fund ETF II EMBL Ventures, a leading early stage European life science venture capital firm, today announces that Boehringer Ingelheim has exercised its option to...